Tamoxifen and prevention

Ursin, Giske; Spicer, Darcy; Pike, Malcolm C.; Bluming, Avrum Z.; Fugh‐Berman, Adriane; Epstein, Sol

doi:10.1016/0140-6736(93)90462-p

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mammographic density has also been shown to change with regimens known to increase or decrease breast cancer risk, such as decreased density with the antiestrogen tamoxifen (5,6), menopause (7), and increased density with postmenopausal hormone therapy use (8,9).…”

Section: Introductionmentioning

confidence: 99%

Plasma Levels of Enterolactone and Percentage Mammographic Density among Postmenopausal Women

Stuedal

Gram

Bremnes

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Aims: Certain phytoestrogens, such as lignans, may protect against developing breast cancer. Enterolactone is a lignan metabolite produced by the intestinal flora from dietary precursors such as whole grains, vegetables, and fruits. Enterolactone has been shown to have weak estrogenic and antiestrogenic properties. We decided to examine the association between plasma levels of enterolactone and mammographic density, a biomarker for breast cancer risk. Methods: We included data from postmenopausal women ages 55 and older who participated in a cross-sectional mammogram study in Tromsø, Norway. Mammograms, plasma enterolactone measurements, as well as information on anthropometric and hormonal/reproduction factors were available on 616 women. We assessed mammographic density using a previously validated computer-assisted method. We estimated correlation coefficients and conducted multiple regression analyses. Results: Mean mammographic density increased slightly across quartiles of enterolactone; the women in the highest quartile had, on average, 3.1% (absolute difference) higher percentage mammographic density compared with the lowest quartile (P trend < 0.01). After adjustment for age, body mass index, number of full-term pregnancies, age at first birth, and use of postmenopausal hormone therapy, the mean difference in density was reduced to 2.0% (P trend = 0.05). Results were similar when restricted to the 454 current hormone nonusers. The fully adjusted statistical model explained 28.3% of the total variability in mammographic percentage density, with body mass index contributing 18.2% and enterolactone only 0.9%. Conclusion: In our study, higher levels of enterolactone were associated with slightly higher percentage mammographic density. Our results suggest that if higher enterolactone levels reduce the risk of developing breast cancer in postmenopausal women, then this effect is not through lowering mammographic density. (Cancer Epidemiol Biomarkers Prev 2005;14(9):2154 -9)

show abstract

Section: Introductionmentioning

confidence: 99%